AMGN
AmgenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull: successful late-stage readouts, stable biologics demand, and continued buybacks drive EPS and multiple expansion toward the analyst high.
Posture
Mixed
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Biosimilar competition driving pricing/volume erosion
Momentum
36
Value
64
Sentiment
47
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $333.98 · Bull $425.00 · Bear $180.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-23 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $355.68
Why
Momentum36 · Δ7d +0.8
Value64 · Δ7d +0.4
Sentiment47 · Δ7d +6.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
36
34% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+12.2
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.6
Sentiment
47
33% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+7.8
Why this grade
Composite grade C. Momentum 35.7 / Value 64.3 / Sentiment 46.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$177.63B
Beta
0.46
Shares Out
538.48M
P/E (TTM)
24.8
P/S (TTM)
4.80
P/FCF (TTM)
26.60
Rev YoY
+12.4%
EPS YoY
+13.6%
Gross Margin
+69.1%
Op Margin
+24.8%
Net Debt
$48.13B
Current Ratio
1.28
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology